Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 6/20 | 0.77 |
| ▸ | MAOB | P27338 | 3/20 | 0.72 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.68 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.58 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.57 |
| ▸ | CNR2 | P34972 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412560 | 1.00 | NR4A2 (0.77) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL8193954 | 0.88 | NR4A2 (0.72) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL1795022 | 0.87 | MEN1 (0.75) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL26574732 | 0.87 | MEN1 (0.70) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL339009 | 0.87 | NR4A2 (1.00) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL30207018 | 0.87 | NR4A2 (1.00) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL7908051 | 0.87 | SRD5A2 (0.85) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL2928585 | 0.86 | NR4A2 (0.58) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| Hydrochloric Acid SCHEMBL4748074 | 0.85 | NR4A2 (0.97) | NR4A2MAOBSMPD1SRD5A2PTPN1 | |
| SCHEMBL3442746 | 0.85 | NR4A2 (0.79) | NR4A2MAOBSMPD1SRD5A2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002280-B1 | CYCLIC TRIAZO AND DIAZO SODIUM CHANNEL BLOCKERS | UNIV GREENWICH (GB) | 2023-05-24 | — | — | EP | disclosed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11072576-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2021-07-27 | — | — | US | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | PHARMAKEA, INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3601250-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | Pharmakea, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20190345094-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY | 2019-11-14 | — | — | US | disclosed |
| EP-0629232-A1 | FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND ALIPHATIC AMINES | CHEVRON CHEMICAL COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0626994-A1 | FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND POLY(OXYALKYLENE) AMINES | CHEVRON CHEMICAL COMPANY (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5366519-A | Antideposit agents for fuels | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994020062-A2 | BALANOIDS AS PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1994-09-15 | — | — | WO | disclosed |
| WO-1994014926-A1 | POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND FUEL COMPOSITIONS CONTAINING THE SAME | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994014928-A1 | FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND ALIPHATIC AMINES | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994014930-A1 | FUEL ADDITIVE COMPOSITIONS CONTAINING POLY(OXYALKYLENE) HYDROXYAROMATIC ESTERS AND POLY(OXYALKYLENE) AMINES | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
| US-5223510-A | ALKYLAMINOALKYL DERIVATIVES OF BENZOFURAN, BENZOTHIOPHENE, INDOLE AND INDOLIZINE, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1993-06-29 | — | — | US | disclosed |
| EP-0135838-A2 | 3-Phenyl-4-methoxycarbonyl pyrazoles, process for their preparation and their use against plant growth | BASF Aktiengesellschaft (DE) | 1985-04-03 | — | — | EP | disclosed |
| EP-0051828-B1 | N-BENZOYL-ALPHA-ANILINO ALKANE CARBOXYLIC ACIDS, SALTS AND ESTERS THEREOF, PROCESS FOR PRODUCING THE SAME AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | A. Nattermann & Cie. GmbH (DE) | 1984-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345094-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | NR4A2 803/4885MAOB 4311/4885SMPD1 1677/4885 |
| US-11072576-B2 | Compositions and methods for glucose transport inhibition | SLC2A1, SLC2A4, SLC2A3 | NR4A2 803/4885MAOB 4311/4885SMPD1 1677/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | NR4A2 4610/4885MAOB 1336/4885SMPD1 73/4885 |
| US-20200048218-A1 | APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK 1) INHIBITOR COMPOUNDS | BAX, BAD, BCL2 | NR4A2 2830/4885MAOB 4327/4885SMPD1 1892/4885 |
| US-10570123-B2 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | NR4A2 4610/4885MAOB 1336/4885SMPD1 73/4885 |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | BAX, BAD, BCL2 | NR4A2 2830/4885MAOB 4327/4885SMPD1 1892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.